TY - JOUR
T1 - Phosphodiesterase type 5 inhibitors usage and prostate cancer
T2 - A match-paired analysis
AU - Machen, G. Luke
AU - Rajab, M. Hasan
AU - Pruszynski, Jessica
AU - Coffield, K. Scott
N1 - Publisher Copyright:
© Translational Andrology and Urology.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Background: To treat erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5i) are commonly used. However, to date, only a few studies exist evaluate a possible effect on the incidence of prostate cancer. One such study completed by the authors' institution suggested men who use PDE5i for ED may have a lower incidence of prostate cancer. This study was meant to address some of the shortcomings of the former study and further characterize the link between prostate cancer and PDE5i use. Methods: A retrospective, match-paired analysis was undertaken: 5,717 patients were identified between 2000 and 2011; a 1:2 match pair analysis ultimately identified 394 cases with cancer and 788 controls without cancer. Pairs were matched based on age, ethnicity, and PSA value. Results: No correlation existed between PDE5i use and prostate cancer [OR 1.02, 95% confidence interval (CI): 0.78-1.35, P=0.8842] or diabetes mellitus and prostate cancer (OR 1.12, 95% CI: 0.84-1.48, P=0.4499). A statistically significant correlation was demonstrated with PSA and prostate cancer (OR 1.48, 95% CI: 1.38-1.58, P < 0.0001). Conclusions: The data suggest that there is essentially no association with PDE5i use and prostate cancer.
AB - Background: To treat erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5i) are commonly used. However, to date, only a few studies exist evaluate a possible effect on the incidence of prostate cancer. One such study completed by the authors' institution suggested men who use PDE5i for ED may have a lower incidence of prostate cancer. This study was meant to address some of the shortcomings of the former study and further characterize the link between prostate cancer and PDE5i use. Methods: A retrospective, match-paired analysis was undertaken: 5,717 patients were identified between 2000 and 2011; a 1:2 match pair analysis ultimately identified 394 cases with cancer and 788 controls without cancer. Pairs were matched based on age, ethnicity, and PSA value. Results: No correlation existed between PDE5i use and prostate cancer [OR 1.02, 95% confidence interval (CI): 0.78-1.35, P=0.8842] or diabetes mellitus and prostate cancer (OR 1.12, 95% CI: 0.84-1.48, P=0.4499). A statistically significant correlation was demonstrated with PSA and prostate cancer (OR 1.48, 95% CI: 1.38-1.58, P < 0.0001). Conclusions: The data suggest that there is essentially no association with PDE5i use and prostate cancer.
KW - Erectile dysfunction (ED)
KW - Phosphodiesterase inhibitors
KW - Prostate cancer
KW - Prostate neoplasm
UR - http://www.scopus.com/inward/record.url?scp=85032278844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032278844&partnerID=8YFLogxK
U2 - 10.21037/tau.2017.06.02
DO - 10.21037/tau.2017.06.02
M3 - Article
C2 - 29184786
AN - SCOPUS:85032278844
SN - 2223-4683
VL - 6
SP - 879
EP - 882
JO - Translational Andrology and Urology
JF - Translational Andrology and Urology
IS - 5
ER -